Mucopolysaccharidosis Type I definition

Mucopolysaccharidosis Type I or "MPS I" means a condition in which individuals are missing an enzyme to break down large sugar molecules. This disorder can impact many different organs and tissue leading to developmental delays if not identified and treated early.

Examples of Mucopolysaccharidosis Type I in a sentence

  • The Commission for Public Health with respect to adding to the Newborn Screening Program established under G.S. 130A-125 screening tests for Pompe disease, Mucopolysaccharidosis Type I (MPS I), and X-Linked Adrenoleukodystrophy (X-ALD).

  • The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I.

  • Eye protection:Tightly sealing safety goggles with lenses made of safety glass (EN 166).

  • Neuro- pathology in Mouse Models of Mucopolysaccharidosis Type I, IIIA and IIIB.

  • Incomplete Biomarker Response in Mucopolysaccharidosis Type I Patients After Successful Hematopoietic Stem Cell TransplantationG.

  • The Review will assess the clinical benefits achieved through the use of LSDP medicines, ensure the ongoing viability of the program; and ensure testing and access requirements for the medicine remain appropriate.This Review Protocol for Mucopolysaccharidosis Type I (MPS I) medicine was prepared by HealthConsult.

  • Outcomes of Long-Term Treatment with Laronidase in Patients with Mucopolysaccharidosis Type I.

  • The respondents and participants are all in year 3 of their study.

  • A Humoral Immune Response Alters the Distribution of Enzyme Replacement Therapy in Murine Mucopolysaccharidosis Type I.

  • In addition, the SACHDNC recommended two ad- ditional disorders to the Secretary, Mucopolysaccharidosis Type I and Adrenoleukodystrophy.Hawai‘i has responded to each new addition to the RUSP us- ing the community decision making process with the NBMSP Advisory Committee when the NBS laboratory methodology has been validated.

Related to Mucopolysaccharidosis Type I

  • Vaccine means a specially prepared antigen which, upon administration to a person, will result in immunity and, specifically for the purposes of this rule, shall mean influenza and pneumococcal vaccines.

  • thalassemia means a group of inherited disorders characterised by reduced or absent amounts of haemoglobin.

  • muscular dystrophy means a group of hereditary genetic muscle disease that weakens the muscles that move the human body and persons with multiple dystrophy have incorrect and missing information in their genes, which prevents them from making the proteins they need for healthy muscles. It is characterised by progressive skeletal muscle weakness, defects in muscle proteins, and the death of muscle cells and tissue;

  • Embryo or "fetus" means the developing human organism from conception until time of birth.

  • MI 61-101 means Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions;

  • Cannabinoid means any of the chemical compounds that are the active constituents of marijuana.

  • Opioid antagonist means a drug that binds to opioid

  • Biological safety cabinet means a containment unit suitable for the preparation of low to moderate risk agents where there is a need for protection of the product, personnel, and environment, according to National Sanitation Foundation (NSF) Standard 49.

  • Cannabinoid edible means food or potable liquid into which a cannabinoid concentrate, cannabinoid extract or dried marijuana leaves or flowers have been incorporated.

  • haemophilia means an inheritable disease, usually affecting only male but transmitted by women to their male children, characterised by loss or impairment of the normal clotting ability of blood so that a minor would may result in fatal bleeding;

  • Prosthesis means an artificial substitute for a missing body part.

  • Cardiopulmonary resuscitation or "CPR" means artificial ventilation or external

  • HIV means human immunodeficiency virus.

  • Opioid antidote means any drug, regardless of dosage amount or method of administration, which has been approved by the United States Food and Drug Administration (FDA) for the treatment of an opioid overdose. “Opioid antidote” includes, but is not limited to, naloxone hydrochloride, in any dosage amount, which is administered through nasal spray or any other FDA-approved means or methods.

  • Total tetrahydrocannabinol means the sum of the percentage by weight of tetrahydrocannabinolic acid multiplied by eight hundred seventy-seven thousandths plus the percentage of weight of tetrahydrocannabinol.

  • Conventional filtration treatment means a series of processes including coagulation, flocculation, sedimentation, and filtration resulting in substantial particulate removal.

  • Corrosion inhibitor means a substance capable of reducing the corrosivity of water toward metal plumbing materials, especially lead and copper, by forming a protective film on the interior surface of those materials.

  • COVID-19 symptoms means fever of 100.4 degrees Fahrenheit or higher, chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, or diarrhea, unless a licensed health care professional determines the person’s symptoms were caused by a known condition other than COVID-19.

  • Biomarker means a parameter or characteristic in a patient or Patient Sample, the measurement of which is useful (a) for purposes of selecting appropriate therapies or patient populations or monitoring disease susceptibility, severity or state, or monitoring therapies for such patient and/or (b) for predicting the outcome of a particular treatment of such patient.

  • Phase III Clinical Trial means a large, controlled or uncontrolled Clinical Study that would satisfy the requirements of 21 CFR 312.21(c), intended to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling.